Literature DB >> 32299669

Grip Strength and Walking Pace and Cardiovascular Disease Risk Prediction in 406,834 UK Biobank Participants.

Claire E Welsh1, Carlos A Celis-Morales1, Frederick K Ho2, Rosemary Brown1, Daniel F Mackay2, Donald M Lyall2, Jana J Anderson2, Jill P Pell2, Jason M R Gill1, Naveed Sattar1, Paul Welsh1, Stuart R Gray3.   

Abstract

OBJECTIVE: To investigate whether the addition of grip strength and/or self-reported walking pace to established cardiovascular disease (CVD) risk scores improves their predictive abilities. PATIENTS AND METHODS: A total of 406,834 participants from the UK Biobank, with baseline measurements between March 13, 2006, and October 1, 2010, without CVD at baseline were included in this study. Associations of grip strength and walking pace with CVD outcomes were investigated using Cox models adjusting for classical risk factors (as included in established risk scores), and predictive utility was determined by changes in C-index and categorical net reclassification index.
RESULTS: Over a median of 8.87 years of follow-up (interquartile range 3, 8.25-9.47 years), there were 7274 composite fatal/nonfatal events (on the basis of the American College of Cardiology/American Heart Association [ACC/AHA] outcome) and 1955 fatal events (on the basis of the Systematic Coronary Risk Evaluation [SCORE] risk score). Both grip strength and walking pace were inversely associated with CVD outcomes after adjusting for classical risk factors. Addition of grip strength (change in C-index: ACC/AHA, +0.0017; SCORE, +0.0047), usual walking pace (ACC/AHA, +0.0031; SCORE, +0.0130), and both combined (ACC/AHA, +0.0041; SCORE, +0.0148) improved the C-index and also improved the net reclassification index (grip, +0.55%; walking pace, +0.53%; combined, 1.12%).
CONCLUSION: The present study has found that the addition of grip strength or usual walking pace to existing risk scores results in improved CVD risk prediction, with an additive effect when both are added. As both these measures are cheap and easy to administer, these tools could provide an important addition to CVD risk screening, although further external validation is required.
Copyright © 2020 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32299669     DOI: 10.1016/j.mayocp.2019.12.032

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  11 in total

1.  Associations of handgrip strength with morbidity and all-cause mortality of cardiometabolic multimorbidity.

Authors:  Yanqiang Lu; Guochen Li; Pietro Ferrari; Heinz Freisling; Yanan Qiao; Luying Wu; Liping Shao; Chaofu Ke
Journal:  BMC Med       Date:  2022-06-03       Impact factor: 11.150

2.  The association of grip strength with cardiovascular diseases and all-cause mortality in people with hypertension: Findings from the Prospective Urban Rural Epidemiology China Study.

Authors:  Weida Liu; Darryl P Leong; Bo Hu; Lap AhTse; Sumathy Rangarajan; Yang Wang; Chuangshi Wang; Fanghong Lu; Yindong Li; Salim Yusuf; Lisheng Liu; Wei Li
Journal:  J Sport Health Sci       Date:  2020-10-19       Impact factor: 7.179

Review 3.  Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis.

Authors:  Fanny Petermann-Rocha; Viktoria Balntzi; Stuart R Gray; Jose Lara; Frederick K Ho; Jill P Pell; Carlos Celis-Morales
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-11-23       Impact factor: 12.910

Review 4.  Whey Protein, Leucine- and Vitamin-D-Enriched Oral Nutritional Supplementation for the Treatment of Sarcopenia.

Authors:  Emanuele Cereda; Roberto Pisati; Mariangela Rondanelli; Riccardo Caccialanza
Journal:  Nutrients       Date:  2022-04-06       Impact factor: 5.717

5.  Muscle strength and incidence of depression and anxiety: findings from the UK Biobank prospective cohort study.

Authors:  Verónica Cabanas-Sánchez; Irene Esteban-Cornejo; Solange Parra-Soto; Fanny Petermann-Rocha; Stuart R Gray; Fernando Rodríguez-Artalejo; Frederick K Ho; Jill P Pell; David Martínez-Gómez; Carlos Celis-Morales
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-06-08       Impact factor: 12.063

6.  Physical Function and Subsequent Risk of Cardiovascular Events in Older Adults: The Atherosclerosis Risk in Communities Study.

Authors:  Xiao Hu; Yejin Mok; Ning Ding; Kevin J Sullivan; Pamela L Lutsey; Jennifer A Schrack; Priya Palta; Kunihiro Matsushita
Journal:  J Am Heart Assoc       Date:  2022-08-31       Impact factor: 6.106

7.  Mediating effects of lower extremity function on the relationship between night sleep duration and cardiovascular disease risk: a cross-sectional study in elderly Chinese without cardiovascular diseases.

Authors:  Hui Zhang; Xiaoyu Chen; Peipei Han; Weibo Ma; Yuanyuan Zhang; Peiyu Song; Yunxiao Wu; Yibo Zhu; Zhengxing Jiang; Ming Cai; Qi Guo; Hong Wang
Journal:  BMJ Open       Date:  2021-07-08       Impact factor: 2.692

8.  Absolute and relative grip strength as predictors of cancer: prospective cohort study of 445 552 participants in UK Biobank.

Authors:  Solange Parra-Soto; Jill P Pell; Carlos Celis-Morales; Frederick K Ho
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-12-24       Impact factor: 12.063

9.  Association of sarcopenia with incident osteoporosis: a prospective study of 168,682 UK biobank participants.

Authors:  Fanny Petermann-Rocha; Lyn D Ferguson; Stuart R Gray; Irene Rodríguez-Gómez; Naveed Sattar; Stefan Siebert; Frederick K Ho; Jill P Pell; Carlos Celis-Morales
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-07-15       Impact factor: 12.910

10.  Associations between grip strength and incident type 2 diabetes: findings from the UK Biobank prospective cohort study.

Authors:  Frederick K Ho; Stuart Robert Gray; Carlos Celis-Morales; Jirapitcha Boonpor; Solange Parra-Soto; Fanny Petermann-Rocha; Gerson Ferrari; Paul Welsh; Jill P Pell; Naveed Sattar; Jason Martin Regnald Gill
Journal:  BMJ Open Diabetes Res Care       Date:  2021-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.